Virologic (NASDAQ:VLGC)
Historical Stock Chart
From Jul 2019 to Jul 2024
ViroLogic and ACLARA to Mail Revised Definitive Proxy for
Proposed Merger
New Date Set for Stockholder Meetings
SOUTH SAN FRANCISCO, Calif. and MOUNTAIN VIEW, Calif., Nov. 8
/PRNewswire-FirstCall/ -- ViroLogic, Inc., (NASDAQ:VLGC) and ACLARA
BioSciences, Inc. (NASDAQ:ACLA) today announced that they will convene their
respective annual stockholder meetings at 9:00 a.m., Pacific Time, on Friday,
December 10, 2004.
At the meetings, ViroLogic and ACLARA stockholders will be asked to approve
certain matters related to the previously announced merger agreement between
the companies, which was amended on October 18, 2004. The ViroLogic
stockholders will be asked to approve, among other things, the issuance of
shares of ViroLogic common stock in the proposed transaction, as well as an
increase in the authorized common stock of ViroLogic. The ACLARA stockholders
will be asked, among other things, to approve and adopt the amended merger
agreement and approve the merger.
The ViroLogic meeting will be held at 345 Oyster Point Boulevard, South San
Francisco, California. The ACLARA meeting will be held 1288 Pear Avenue,
Mountain View, California. Stockholders at the close of business on November
2, 2004, the record date for each meeting, will be eligible to vote at the
meetings. ViroLogic and ACLARA intend to begin mailing a joint proxy
statement/prospectus to their stockholders on or about November 9, 2004. The
transaction is expected to close shortly after the stockholder meetings,
assuming ViroLogic and ACLARA receive stockholder approval and satisfaction of
other closing conditions.
The proposed merger transaction was first announced in a joint press release on
June 1, 2004. Under the terms of the previously announced merger agreement,
each outstanding share of ACLARA common stock will be exchanged for 1.7 shares
of ViroLogic common stock and 1.7 contingent value rights (CVR). On October
18th, the companies modified the terms of the CVR in the definitive merger
agreement previously executed by the companies; however, the exchange ratios
remain unchanged.
ABOUT VIROLOGIC
ViroLogic is a biotechnology company advancing individualized medicine by
discovering, developing and marketing innovative products to guide and improve
treatment of serious infectious diseases such as AIDS and hepatitis. The
Company's products are designed to help doctors optimize treatment regimens for
their patients that lead to better outcomes and reduced costs. The Company's
technology is also being used by numerous biopharmaceutical companies to
develop new and improved antiviral therapeutics and vaccines targeted at
emerging drug-resistant viruses. More information about the Company and its
technology can be found on its web site at http://www.virologic.com/.
ABOUT ACLARA
Founded in 1995, ACLARA is a biotechnology company working to provide
physicians and researchers products and services to make personalized medicine
a reality through its protein-based assay technology - the eTag(TM) System.
ACLARA is dedicated to unlocking the power of pathway biology to accelerate the
development of next-generation targeted therapeutics, recognizing the most
appropriate patients for approved therapies and identifying the highly-
specific, protein-based biomarkers that will enable physicians to create truly
personalized treatment regimens for patients suffering from cancer and other
life-threatening disorders.
ACLARA is commercializing its proprietary eTag System to enhance and accelerate
drug discovery research and the preclinical and clinical development of
targeted therapeutics. ACLARA's technology may also enable the development of
highly-specific, protein-based diagnostics capable of providing physicians with
a powerful tool for creating personalized treatment regimens for patients
suffering from serious and difficult-to-treat cancers. For more information on
ACLARA please visit the Company's web site at http://www.aclara.com/.
ADDITIONAL INFORMATION
ViroLogic, Inc. has filed with the Securities and Exchange Commission a
registration statement on Form S-4 (File No. 333-120211) that includes an
amended joint proxy statement/prospectus of ViroLogic and ACLARA and other
relevant documents in connection with the proposed transaction. Investors and
security holders of ViroLogic and ACLARA are advised to read the amended joint
proxy statement/prospectus, and other documents filed by ViroLogic and ACLARA,
because they will contain important information about ViroLogic, ACLARA and the
proposed transaction. Investors and security holders may obtain a free copy of
the amended joint proxy statement/prospectus, and other documents filed by
ViroLogic and ACLARA at the Securities and Exchange Commission's web site at
http://www.sec.gov/. The amended joint proxy statement/prospectus and such
other documents may also be obtained from ViroLogic by directing such request
to ViroLogic, Inc., 345 Oyster Point Blvd; South San Francisco, California
94080, Attention: Investor Relations. The amended joint proxy
statement/prospectus and such other documents may also be obtained from ACLARA
by directing such request to ACLARA BioSciences, Inc., 1288 Pear Avenue,
California 94043, Attention: Investor Relations. ViroLogic, ACLARA and their
respective executive officers and directors may be deemed to be participants in
the solicitation of proxies from stockholders of ViroLogic and ACLARA with
respect to the transactions contemplated by the amended merger agreement. A
description of any interests that ViroLogic's or ACLARA's directors and
executive officers have in the proposed merger is included in the amended joint
proxy statement/prospectus. Information regarding ViroLogic officers and
directors is included in ViroLogic's 10-K/A filed with the Securities and
Exchange Commission on April 23, 2004. Information regarding ACLARA's officers
and directors is included in ACLARA's 10-K/A filed with the Securities and
Exchange Commission on April 29, 2004. These materials are available free of
charge at the Securities and Exchange Commission's web site at
http://www.sec.gov/ and from ViroLogic and ACLARA.
FORWARD LOOKING STATEMENTS
Certain statements in this press release are forward-looking, including
statements relating to the timing of completion of the proposed merger. These
forward-looking statements are subject to risks and uncertainties and other
factors, which may cause actual results to differ materially from the
anticipated results or other expectations expressed in such forward-looking
statements. These risks and uncertainties include, but are not limited to:
risks related to the inability to obtain, or meet conditions imposed for,
governmental and other approvals of the merger, including approval by
stockholders of the companies; risks related to any uncertainty surrounding the
merger, and the costs related to the merger; risks related to the
implementation of ViroLogic's distribution agreement with Quest; whether others
introduce competitive products; the timing of pharmaceutical company clinical
trials; whether payors will authorize reimbursement for its products; whether
the FDA or any other agency will decide to regulate the combined company's
products or services; whether the combined company will encounter problems or
delays in automating its processes; whether intellectual property underlying
ViroLogic's PhenoSense technology and ACLARA's eTag System is adequate; the
ultimate validity and enforceability of the companies' patent applications and
patents; the possible infringement of the intellectual property of others and
whether licenses to third party technology will be available; and whether the
combined company is able to build brand loyalty and expand revenues. For a
discussion of other factors that may cause ViroLogic's and ACLARA's actual
events to differ from those projected, please refer to each Company's most
recent annual reports on Form 10-K and quarterly reports on Form 10-Q, as well
as other subsequent filings with the Securities and Exchange Commission.
DATASOURCE: ViroLogic, Inc.
CONTACT: Investor Relations, ViroLogic, +1-650-635-1100, or
, or Investor Relations, ACLARA, +1-650-210-1200, or
Web site: http://www.aclara.com/
Web site: http://www.virologic.com/